Cantargia Reiterated as Buy on Nadunolimab’s Strong Early Data and Pipeline Progress; Price Target Maintained at SEK14

In a report released today, Sara Nik from H.C. Wainwright reiterated a Buy rating on Cantargia AB, with a price target of SEK14.00.

Sara Nik has given his Buy rating due to a combination of factors tied to nadunolimab’s emerging clinical profile and Cantargia’s broader pipeline strategy. Early Phase 1b/2a findings in high‑risk MDS show that all evaluable patients achieved complete remission on the nadunolimab plus azacitidine regimen, providing an encouraging efficacy signal with a generally manageable safety profile.

These data are viewed as validating the drug’s mechanism and expanding its potential beyond solid tumors into hematologic cancers, supported by strong IL1RAP expression on leukemic stem cells. Coupled with a pivotal‑ready pancreatic cancer program, an expanding investigator‑sponsored trial network, and the unchanged SEK14 price target, the stock is seen as an attractive entry opportunity for investors at current levels.